The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100. Predicted molecular weight: 56 kDa.
1/10 - 1/50.
Tissue specificityBrain, heart, liver and kidney.
Involvement in diseaseDefects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:614504]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.
Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family. Contains 1 WHEP-TRS domain.
ab71305 at 1/50 dilution staining HARS - Aminoterminal in human hepatocarcinoma tissue section by Immunohistochemistry (Formalin/ PFA fixed paraffin-embedded sections). A peroxidase conjugated secondary antibody was used followed by DAB staining.
References for Anti-HARS antibody - Aminoterminal end (ab71305)
has not yet been referenced specifically in any publications.
Publishing research using ab71305? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"